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p53 and angiogenesis in non-small-cell lung cancer
Reply to the letter from Giatromanolaki and
Koukourakis
Sir
We completely agree with Dr Giatromanolaki about the controver-
sial prognostic role of p53 expression in human cancers and, in
particular, in lung cancer. There are in fact several studies that fail
to evidence any statistical association between p53 alterations and
poor prognosis in NSCLC (McLaren et al, 1992; Kashii et al,
1995; Kwa et al, 1996; Nishio et al, 1996) and others that find an
association between p53 alterations and a favourable behaviour.
However, several other studies, which evaluated both p53 muta-
tions and p53 nuclear overexpression, have underlined a strong
statistical association between p53 alterations and poor prognosis
in this type of cancer (Quinlan et al, 1992; Horio et al, 1993;
Mitsudomi et al, 1993; Fontanini et al, 1995a; Harpole et al, 1995;
Dalquen et al, 1996; Irie et al, 1996; Dosaka-Akita et al, 1997;
Fontanini et al, 1997, Fukuyama et al, 1997), stimulating further
investigation in this field. As regards the discrepancies that arise
between these studies, we have identified some possible causes:
(1) the cohorts ofpatients analysed (prospective or retrospective);
(2) the different stages of the tumours; (3) the histological types
investigated; (4) the methodologies used. We believe that the most
correct analyses tending towards a prognostic evaluation of a
specific factor should use prospective and consecutive series of
patients, because retrospective cohorts more often lead to the
introduction ofpotential biases.
With regard to the evaluation ofthe relationship between angio-
genesis, oncogenes and tumour-suppressor genes, we believe that
in this field also there is a long way to go. In fact, very few studies
have been performed in this respect, and itis too restrictive to draw
final conclusions on the basis of only two investigations, mainly
because these analyses disagree on some points. We are not
completely sure that anti-FVIII antibodies are less specific than
other types of endothelium-related antibodies as the anti-FVIII
antibody has been defined as being the most specific marker for
endothelial cells (Weidner, 1995; Folkman and Weidner, 1996),
although it may be a little less sensitive in non-expert hands.
Moreover, it has been reported by Folkman and Weidner (1996)
that, although apparently more sensitive, CD31 strongly cross-
reacts with plasma cells (DeYoung et al, 1993; Longacre et al,
1994), and this complication can markedly obscure the micro-
vessels in tumours with a prominent plasmacellular inflammatory
background. Weidner (1995) reports that a valid alternative to
FVIII antibodies may be represented by the anti-CD34 antibody
and, recently, Tomisaki et al (1996) demonstrated a very strong
correlation between FVIII and CD34 immunoreactivity in
colorectal cancer (r = 0.956, P = 0.01). Like antibodies to FVIII,
anti-CD31 and anti-CD34 do not immunostain all intratumoral
microvessels, and it would be useful to dispose of new antibodies
raised against proliferating or activated endothelial cells.
However, we would like to underline that anti-FVIII antibodies
have been used in most of the analyses on vascular count
performed in NSCLC (five out of seven), and a significant associ-
ation between vascular count and poorprognosis has been found in
all of these series (Macchiarini et al, 1992; Yamasaki et al, 1994;
Fontanini et al, 1995b; Angeletti et al, 1996; Giatromanolaki et al,
1996; Harpole et al, 1996).
According to Weidner (1995) and Folkman (1995), we evalu-
ated the vascular count in our tumours in the areas with a greater
number of microvessels ('hot spot') after scanning more than one
section ofthe tumour. The 'hot spot', so defined, is considered as
being representative of tumoral angiogenesis by these authors,
despite the many discussions held in this field so far. In general,
we agree with the concept that tumour cells have different angio-
genic potentials and that the 'hot spot', ifcarefully identified by an
expert pathologist, may provide reliable information on the angio-
genic pattern ofa tumour. From this point ofview, we believe that
the association that we found between p53 and vascular count in
our series ofpatients (Fontanini et al, 1997) should be considered
exciting, although it is not in agreement with the data by
Giatromanolaki et al (1996) - it represents, on the one hand, a
further contribution to the discussion on the relationship between
tumour-suppressor genes and angiogenesis and, on the other hand,
it prompts us to perform further studies as suggested by Dr
Giatromanolaki.
G Fontanini, Department ofOncology, Division ofPathology,
University ofPisa, via Roma 57, 56126 Pisa, Italy
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